BGAI
SRPT icon

Bruce G. Allen Investments’s Sarepta Therapeutics SRPT Stock Holding History

Bruce G. Allen Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12
Closed -$258 – 1141
2025
Q4 		$258 Hold
12
– – ﹤0.01% 1034
2025
Q3 		$231 Sell
12
-41
-77% -$731 ﹤0.01% 1045
2025
Q2 		$906 Buy
+53
New +$2.26K ﹤0.01% 844

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bruce G. Allen Investments's SRPT Position: Q1 2026 in Review

Bruce G. Allen Investments sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 12 shares — an estimated $258 sold.

Bruce G. Allen Investments first reported a position in SRPT in Q2 2025 and held it in 3 quarters. The position peaked at $906 in Q2 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Bruce G. Allen Investments reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bruce G. Allen Investments sold 12 Sarepta Therapeutics shares in Q1 2026, an estimated $258.
  • Bruce G. Allen Investments first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 3 quarters.
  • Bruce G. Allen Investments's Sarepta Therapeutics position peaked at $906 in Q2 2025.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Bruce G. Allen Investments's 13F filing for Q1 2026, filed 8 May 2026.